159PPrognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting

ConclusionsOur multicentre and multi-assay study suggests that the density of CD8 positive cells in the tumour core is a robust prognostic factor in MIBC. Further investigation of PD-L1 and CD3 cell density is warranted.Legal entity responsible for the studyDefiniens AG; The Walter and Eliza Hall Institute of Medical Research; University of St Andrews.FundingDefiniens AG.DisclosureK. Nekolla: Full / Part-time employment, Definiens is a full subsidiary of AstraZeneca: Definiens AG. N. Brieu: Full / Part-time employment, Definiens is a full subsidiary of AstraZeneca: Definiens AG. C.G. Gavriel: Research grant / Funding (self), Definiens is a full subsidiary of AstraZeneca: Definiens AG. M. Widmaier: Full / Part-time employment, Definiens is a full subsidiary of AstraZeneca: Definiens AG. A. Budco: Full / Part-time employment, Definiens is a full subsidiary of AstraZeneca: Definiens AG. D. Medrikova: Full / Part-time employment, Definiens is a full subsidiary of AstraZeneca: Definiens AG. I. Kanchev: Full / Part-time employment, Definiens is a full subsidiary of AstraZeneca: Definiens AG. M. Testori: Full / Part-time employment, Definiens is a full subsidiary of AstraZeneca: Definiens AG. J. Chan: Full / Part-time employment, Definiens is a full subsidiary of AstraZeneca: Definiens AG. D.J. Harrison: Advisory / Consultancy, Member: Scientific Advisory Board: Definiens AG; Full / Part-time employment: NuCana plc; Leadership role, Director: Industrial Centre for AI Research in Dig...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research